Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | PELI1 | Q96FA3 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 2/20 | 0.54 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.53 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | VCP | P55072 | 1/20 | 0.52 |
| ▸ | TDP2 | O95551 | 2/20 | 0.51 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenol SCHEMBL28284718 | 0.91 | ALDH1A1 (0.67) | ALDH1A1TSHRALOX15PELI1LMNA | |
| SCHEMBL30469251 | 0.87 | ALDH1A1 (0.78) | ALDH1A1TSHRALOX15PELI1MEN1 | |
| SCHEMBL20557926 | 0.87 | ALDH1A1 (0.78) | ALDH1A1TSHRALOX15PELI1MEN1 | |
| SCHEMBL7838339 | 0.86 | LMNA (0.64) | ALDH1A1TSHRMEN1KMT2ALMNA | |
| SCHEMBL4516641 | 0.86 | TSHR (0.64) | ALDH1A1TSHRALOX15LMNAPGR | |
| SCHEMBL3009086 | 0.86 | ESR1 (0.61) | ALDH1A1TSHRALOX15PELI1MEN1 | |
| Dinitrophenylene SCHEMBL27738809 | 0.86 | TSHR (0.77) | ALDH1A1TSHRALOX15MEN1KMT2A | |
| SCHEMBL6738366 | 0.86 | TSHR (0.76) | ALDH1A1TSHRALOX15MEN1KMT2A | |
| SCHEMBL29526232 | 0.84 | TSHR (0.67) | ALDH1A1TSHRALOX15MEN1KMT2A | |
| SCHEMBL2009026 | 0.84 | TSHR (0.67) | ALDH1A1TSHRALOX15MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | claimed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | claimed |
| CN-108883099-A | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | 石全 | 2018-11-23 | — | — | CN | disclosed |
| EP-2970353-B1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMA (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9890176-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2970353-A2 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105164142-A | Mannose derivatives for the treatment of bacterial infections | VERTEX PHARMA | 2015-12-16 | — | — | CN | disclosed |
| WO-2014165107-A2 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140274930-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-18 | — | — | US | disclosed |
| US-7514556-B2 | Inhibitors of β-lactamase | METHYLGENE INC. (CA) | 2009-04-07 | — | — | US | disclosed |
| US-7514556-B2 | Inhibitors of β-lactamase | METHYLGENE INC. (CA) | 2009-04-07 | — | — | US | disclosed |
| US-6762205-B1 | STEROID SULFATASE INHIBITORS WITHOUT ESTROGENIC SIDE EFFECT ACTION | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 2004-07-13 | — | — | US | disclosed |
| EP-1193250-A1 | PHENYL SULFAMATE DERIVATIVES | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2002-04-03 | — | — | EP | disclosed |
| US-6214842-B1 | TREATING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA TYPICALLY ASSOCIATED WITH OBESITY OR GLUCOSE INTOLERANCE; TREATING DIABETES TYPES I AND II | WYETH | 2001-04-10 | — | — | US | disclosed |
| US-5977105-A | Compounds | ASTRA PHARMAEUTICALS LTD. (GB) | 1999-11-02 | — | — | US | disclosed |
| EP-0865431-A2 | COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 1998-09-23 | — | — | EP | disclosed |
| EP-0852486-A2 | ANTIPLAQUE ORAL COMPOSITION | Colgate-Palmolive Company (US) | 1998-07-15 | — | — | EP | disclosed |
| US-5723500-A | WATER INSOLUBLE, NONCATIONIC, ANTIBACTERIAL, STERICALLY HINDERED PHENOL; MOUTHWASHES, DENTIFRICES | COLGATE-PALMOLIVE COMPANY (US) | 1998-03-03 | — | — | US | disclosed |
| WO-1997020815-A1 | COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1997-06-12 | — | — | WO | disclosed |
| WO-1997010800-A2 | ANTIPLAQUE ORAL COMPOSITION | COLGATE-PALMOLIVE COMPANY (US) | 1997-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | ALDH1A1 711/4885TSHR 3234/4885ALOX15 592/4885 |
| US-20140274930-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | TLR5, TLR1, MANBA | ALDH1A1 1488/4885TSHR 4373/4885ALOX15 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.